Table 2.
Baseline characteristics of participants stratified by dual antiplatelet therapy.
| Characteristics | Ticagrelor/aspires (N = 197) | Clopidogrel/aspirin (N = 190) | P value |
|---|---|---|---|
| NIHSS Median (IQR) | |||
| Age, y, median (IQR) | 62 (55–67) | 61 (55–67) | 0.55 |
| Female, n (%) | 57 (28.9) | 53 (27.9) | 0.82 |
| BMI, kg/m2, median (IQR) | 24.3 (22.6–26.8) | 24.8 (22.6–27.0) | 0.50 |
| Medical history, n (%) | |||
| Hypertension | 117 (59.4) | 121 (63.7) | 0.39 |
| Dyslipidaemia | 15 (7.6) | 14 (7.4) | 0.93 |
| Diabetes mellitus | 47 (23.9) | 49 (25.8) | 0.66 |
| Ischaemic stroke | 35 (17.8) | 38 (20.0) | 0.57 |
| TIA | 4 (2.0) | 7 (3.7) | 0.33 |
| Coronary artery disease | 10 (5.1) | 6 (3.2) | 0.34 |
| Current smoker, n (%) | 86 (43.7) | 85(44.7) | 0.91 |
| Drug use before randomization, n (%) | |||
| Proton-pump inhibitor | 2 (1.0) | 2 (1.1) | 0.97 |
| Statin | 29 (14.7) | 20 (10.5) | 0.21 |
| Aspirin | 57 (28.9) | 40 (21.0) | 0.07 |
| Clopidogrel | 3 (1.5) | 7 (3.7) | 0.18 |
| Ticagrelor | 0 (0.0) | 0 (0.0) | |
| Time from onset to randomization, h, median (IQR) | 15.8 (8.7–20.8) | 14.7 (8.3–20.7) | 0.46 |
| Qualifying event, n (%) | |||
| Minor stroke | 166 (84.3) | 158 (83.2) | 0.77 |
| TIA | 31 (15.7) | 32 (16.8) | |
| NIHSS, median (IQR); mean ± SD | 2(1–3); 1.62 ± 1.14 | 2(1–3); 1.58 ± 1.13 | 0.17 |
| Baseline ABCD2 score, median (IQR) | 5(4,5) | 4.5 (4,5) | 0.94 |
| SSS-TOAST stroke subtype, n (%) | 0.23 | ||
| Large-artery atherosclerosis | 100 (60.2) | 81 (51.3) | |
| Cardioaortic embolism | 5 (3.0) | 2 (1.3) | |
| Small-artery occlusion | 53 (31.9) | 60 (38.0) | |
| Other causes | 4 (2.4) | 7 (4.4) | |
| Undetermined causes | 4 (2.4) | 8 (5.1) |
IQR indicates interquartile range; SD, standard deviation; BMI, body mass index; TIA, transient ischaemic attack; ABCD2, age, blood pressure, clinical features, duration of TIA, and presence of diabetes score squared; SSS-TOAST, Stop Stroke Study-Trial of Org 10172 in Acute Stroke Treatment.